# Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+ Invasive Lobular Breast Cancer

**Authors:** Fangyuan Chen, Sayali Onkar, Jian Zou, Yujia Li, Haley Arbore, Sai Maley, George Tseng, Peter Lucas, Tullia Bruno, Dario Vignali, Julia Foldi, Marija Balic, Adrian Lee, Steffi Oesterreich

PMC · DOI: 10.21203/rs.3.rs-4579052/v1 · Research Square · 2024-08-13

## TL;DR

This study finds that immune cell presence in a specific type of breast cancer correlates with different genetic patterns, which could help predict patient outcomes.

## Contribution

The study identifies novel transcriptomic subtypes and immune infiltration patterns specific to ER+/HER2- invasive lobular breast cancer.

## Key findings

- Two transcriptomic subtypes and five immune infiltration patterns were identified in ER+/HER2- invasive lobular breast cancer.
- A TAM-Low signature correlates with lower infiltration of pro-inflammatory TAM and better patient outcomes in ER+ tumors.

## Abstract

Understanding interplay of breast cancer and microenvironment is critical. Here, we
identified two transcriptomic subtypes and five immune infiltration patterns from
RNA-seq and multiplex immunohistochemistry from 21 ER+/HER2- invasive lobular breast
cancers. The proliferative subtype associated with increased immune infiltration
especially by immunosuppressive regulatory T-cells and macrophages. We also defined a
TAM-Low signature, which associated with lower infiltration of proliferative,
pro-inflammatory TAM, and improved outcome in patients with ER+ tumors.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}
- **Diseases:** inflammatory (MESH:D007249), Breast Cancer (MESH:D001943), TAM (MESH:D020914), tumors (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC11343297